by Elana Gotkine Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study published in the Journal of Clinical Psychopharmacology. Maki Gouda, from the Mitsubishi Tanabe Pharma Corporation in Osaka, Japan, and colleagues examined the association between antipsychotic doses and the risk for TD in clinical practice in a...
Tag: <span>antipsychotic drug</span>
Post
New Guidance Recommends Metformin to Prevent Antipsychotic Weight Gain
Megan Brooks December 20, 2024 3226 Added to Email Alert A new evidence-based guideline recommends prescribing metformin when initiating antipsychotic treatment to help mitigate weight gain in certain instances. There is “good evidence” that metformin can prevent weight gain caused by antipsychotics, first author Aoife Carolan, MPharm, with Saint John of God Hospital and the...
Post
Antipsychotic medications don’t always work the way they’re supposed to
Sixty-eight per cent of nursing home residents who used antipsychotics had more behavioural issues than they did pre-medicationPeer-Reviewed Publication University of Waterloo A new study conducted by researchers at the University of Waterloo analyzed data from nearly 500,000 Canadian patients who lived in nursing homes across Canada between 2000 and 2022. It found that residents who were given...
Post
Study suggests key to antipsychotic-drug–induced obesity
by UT Southwestern Medical Center Effect of risperidone and risperidone + LepAb on body weight, food intake, and glucose tolerance. Female mice (n = 9) were placed on an HFD alone (Ctrl) or an HFD supplemented with risperidone. Mice were treated with either control IgG or LepAb twice weekly. Body weight and food intake were measured. Glucose...
Post
Alarm as FDA fast-tracks first antipsychotic drug for agitation in dementia
by BMJ Newswise — In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia. At a cost of around...
Post
Alarm as FDA fast-tracks first antipsychotic drug for agitation in dementia
by British Medical Journal Credit: Unsplash/CC0 Public Domain In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia. At a cost of...